Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab

Shinya Ashizuka; Nobuko Kuroishi; Koji Nakashima; Haruhiko Inatsu; Toshihiro Kita; Kazuo Kitamura

doi:10.2169/internalmedicine.1791-18

CASE REPORTS

Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab

Shinya Ashizuka, Nobuko Kuroishi, Koji Nakashima, Haruhiko Inatsu, Toshihiro Kita, Kazuo Kitamura

Author information

Keywords: adrenomedullin, Crohn's disease, inflammatory bowel disease, infliximab, mucosal healing, loss of response

JOURNAL OPEN ACCESS

2019 Volume 58 Issue 11 Pages 1573-1576

DOI https://doi.org/10.2169/internalmedicine.1791-18

Browse “Advance online publication” version

Details

Abstract

A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy was started in addition to the conventional infliximab therapy. A few days after, his symptoms went into remission. Endoscopy at 2 and 7 weeks revealed significant mucosal remission without steroid therapy. Adrenomedullin promoted mucosal healing and led to the re-induction of remission in Crohn's disease in a patient with a loss of response to infliximab.

Corresponding author

Register with J-STAGE for free!